MedTrace Logo

Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy

NCT02806752 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-11-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV). Furthermore, the pharmacogenetics effect of inflammatory related genes polymorphism in response to the treatments. To further confirm the role of inflammatory factors in the pathogenesis and advance of PCV.

Conditions

  • Wet Macular Degeneration

Interventions

DRUG

Triamcinolone Acetonide

Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.

DRUG

Ranibizumab

Intravitreal inject 0.5mg of Ranibizumab.

Sponsors & Collaborators

  • Aier School of Ophthalmology, Central South University

    lead OTHER

Principal Investigators

  • Shibo Tang · Aier School of Ophthalmology, Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806752 on ClinicalTrials.gov